ARTICLE | Clinical News
Viibryd vilazodone: Phase III data
June 30, 2014 7:00 AM UTC
Top-line data from the double-blind, U.S. Phase III MD-06 trial in 402 adults with GAD showed that flexible doses of 20-40 mg/day oral Viibryd met the primary endpoint of improving HAM-A total score f...